Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Evans R, Hawkins N, Dequen-O'Byrne P, McCrea C, Muston D, Gresty C, Ghate SR, Fan L, Hettle R, Abrams KR, de Bono J, Hussain M, Agarwal N. Evans R, et al. Among authors: fan l. Target Oncol. 2021 Sep;16(5):613-623. doi: 10.1007/s11523-021-00837-y. Epub 2021 Sep 3. Target Oncol. 2021. PMID: 34478046 Free PMC article.
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: fan l. Pharmacoecon Open. 2022 Nov;6(6):811-822. doi: 10.1007/s41669-022-00338-2. Epub 2022 Aug 29. Pharmacoecon Open. 2022. PMID: 36036344 Free PMC article.
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: fan l. Pharmacoecon Open. 2022 Nov;6(6):899. doi: 10.1007/s41669-022-00372-0. Pharmacoecon Open. 2022. PMID: 36107308 Free PMC article. No abstract available.
9,426 results